Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × B-Cell Malignancies × parsaclisib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Non-Hodgkin 2 Recurrence 1 Neoplasm Metastasis 1 Lymphoma, Large B-Cell, Diffuse 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia 1 B-Cell Malignancies 1

Interventions

parsaclisib 1 itacitinib 1 Rituximab 1 Ifosfamide 1 INCB039110 1 Etoposide 1 Carboplatin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02018861 2023-09-28

A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)

Incyte Corporation

Phase 1/2 Completed

88 enrolled 25 charts

B-Cell Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon ⚡